440 related articles for article (PubMed ID: 17118432)
1. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of unfractionated heparin therapy in children: time for change?
Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
Br J Haematol; 2010 Sep; 150(6):674-8. PubMed ID: 20629660
[TBL] [Abstract][Full Text] [Related]
3. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
Kitchen S; Theaker J; Preston FE
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
[TBL] [Abstract][Full Text] [Related]
4. In vivo age dependency of unfractionated heparin in infants and children.
Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
6. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin.
Newall F; Ignjatovic V; Johnston L; Summerhayes R; Lane G; Cranswick N; Monagle P
Thromb Haemost; 2010 May; 103(5):1085-90. PubMed ID: 20174762
[TBL] [Abstract][Full Text] [Related]
7. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
8. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
9. Analysis of unfractionated heparin dose requirements to target therapeutic anti-Xa intensity during pregnancy.
Clark NP; Delate T; Cleary SJ; Witt DM
Thromb Res; 2010 May; 125(5):402-5. PubMed ID: 19699510
[TBL] [Abstract][Full Text] [Related]
10. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
11. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
12. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
13. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
14. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
15. Anti-factor Xa (anti-Xa) assay.
Newall F
Methods Mol Biol; 2013; 992():265-72. PubMed ID: 23546719
[TBL] [Abstract][Full Text] [Related]
16. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
Barrowcliffe TW; Le Shirley Y
Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
[TBL] [Abstract][Full Text] [Related]
17. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Potze W; Arshad F; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Lisman T
Br J Haematol; 2013 Dec; 163(5):666-73. PubMed ID: 24219333
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
Ip BK; Thomson AR; Moriarty HT
Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
[TBL] [Abstract][Full Text] [Related]
19. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
Cuker A; Ptashkin B; Konkle BA; Pipe SW; Whinna HC; Zheng XL; Cines DB; Pollak ES
J Thromb Haemost; 2009 Jan; 7(1):80-6. PubMed ID: 19017257
[TBL] [Abstract][Full Text] [Related]
20. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
